Feasibility and outcome of genomics-guided treatment selection in advanced cancer - the MEGALiT explorative clinical trial.

Precision cancer medicine (PCM) is key to advancing cancer treatment beyond the standard of care. Genomics-guided treatment selection in advanced cancer is feasible and safe.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 We performed an explorative clinical trial, MEGALiT, to investigate the feasibility, safety, and clinical benefit of genomics-based PCM in advanced cancer.
• 2 MEGALiT recruited adult patients with advanced solid tumors refractory to standard treatment.
• 3 Tumor DNA from newly acquired biopsies or ctDNA were analyzed for alterations targetable with the PD-L1 inhibitor atezolizumab, the MEK inhibitor cobimetinib, the mTOR inhibitor everolimus, or the PARP-inhibitor niraparib.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: